Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongbing Zhang

Showing results (181-190 of 269) with videos related to

Pageof 27
Sort By:
Signal Transduction and Targeted Therapy|December 12, 2023
Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosisJun Wei, Min Li, Zhi Ye, et al.
Cardiovascular Drugs and Therapy|July 14, 2021
SLC7A11/xCT Prevents Cardiac Hypertrophy by Inhibiting FerroptosisXiyu Zhang, Cuiting Zheng, Zhenqiang Gao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 21, 2020
[Preliminary Recommendations for Lung Surgery during 2019 Novel Coronavirus Disease (COVID-19) Epidemic Period]Xin Li, Minghui Liu, Qingchun Zhao, et al.
Journal of Cancer|August 18, 2021
HOTAIR promotes gefitinib resistance through modification of EZH2 and silencing p16 and p21 in non-small cell lung cancerWeiting Li, Yongwen Li, Hongbing Zhang, et al.
Journal of Cancer|April 5, 2024
ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung CancerGuangsheng Zhu, Jinghao Liu, Yongwen Li, et al.
Clinical and Translational Medicine|January 4, 2025
Unravelling the prognostic and operative role of intratumoural microbiota in non-small cell lung cancer: Insights from 16S rRNA and RNA sequencingFuling Mao, Zixuan Hu, Ruifeng Shi, et al.
BMC Cancer|December 5, 2020
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cellsHao Gong, Yongwen Li, Yin Yuan, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 22, 2019
[Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells]Hao Gong, Yin Yuan, Yongwen Li, et al.
Chinese Medical Journal|August 23, 2023
Oncogenic β-catenin-driven liver cancer is susceptible to methotrexate-mediated disruption of nucleotide synthesisFangming Liu, Yuting Wu, Baohui Zhang, et al.
Journal of Proteomics|February 5, 2016
mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundancesXianwei Chen, Yinghui Zhu, Zhaohui Wang, et al.
Pageof 27

Showing results (181-190 of 269) with videos related to

Sort By:
Pageof 27
Signal Transduction and Targeted Therapy|December 12, 2023
Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosisJun Wei, Min Li, Zhi Ye, et al.
Cardiovascular Drugs and Therapy|July 14, 2021
SLC7A11/xCT Prevents Cardiac Hypertrophy by Inhibiting FerroptosisXiyu Zhang, Cuiting Zheng, Zhenqiang Gao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 21, 2020
[Preliminary Recommendations for Lung Surgery during 2019 Novel Coronavirus Disease (COVID-19) Epidemic Period]Xin Li, Minghui Liu, Qingchun Zhao, et al.
Journal of Cancer|August 18, 2021
HOTAIR promotes gefitinib resistance through modification of EZH2 and silencing p16 and p21 in non-small cell lung cancerWeiting Li, Yongwen Li, Hongbing Zhang, et al.
Journal of Cancer|April 5, 2024
ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung CancerGuangsheng Zhu, Jinghao Liu, Yongwen Li, et al.
Clinical and Translational Medicine|January 4, 2025
Unravelling the prognostic and operative role of intratumoural microbiota in non-small cell lung cancer: Insights from 16S rRNA and RNA sequencingFuling Mao, Zixuan Hu, Ruifeng Shi, et al.
BMC Cancer|December 5, 2020
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cellsHao Gong, Yongwen Li, Yin Yuan, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 22, 2019
[Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells]Hao Gong, Yin Yuan, Yongwen Li, et al.
Chinese Medical Journal|August 23, 2023
Oncogenic β-catenin-driven liver cancer is susceptible to methotrexate-mediated disruption of nucleotide synthesisFangming Liu, Yuting Wu, Baohui Zhang, et al.
Journal of Proteomics|February 5, 2016
mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundancesXianwei Chen, Yinghui Zhu, Zhaohui Wang, et al.
Pageof 27